Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent ® for Moderate to Severe Atopic Dermatitis

Conditions: Moderate to Severe Atopic Dermatitis Sponsors: Sanofi; Regeneron Pharmaceuticals Recruiting

Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials